View More Recent Stories
-
Leerink Partners Starts Janux Therapeutics (JANX) at Outperform
-
Janux Therapeutics, Inc. (JANX) Misses Q3 EPS by 18c
-
UBS Starts Janux Therapeutics (JANX) at Buy
-
Stifel Starts Janux Therapeutics (JANX) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Janux Therapeutics (JANX)
-
Janux Therapeutics (JANX) PT Lowered to $42 at Scotiabank
-
Janux Therapeutics, Inc. (JANX) Tops Q2 EPS by 20c
-
Janux Therapeutics (JANX) Announces Updates to Board of Directors

